Table 2 Overview of current Daa combination therapies (ongoing and recently completed trials) with or without PEG-IFN/RBv in clinical development
Company | NS3 Protease Inh. | NS5A Inh. | NS5B Nuc. Inh. | NS5B Non-Nuc. Inh. | Duration of DAA therapy | DAAs alone | DAAs+ RBV | DAAs+ IFN/RBV | Prior treatment | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
Roche | Danoprevir*(100 mg TID - 900 mgBID) | RG 7128 (500 mg or 1000 mg BID) | 1-2 weeks | ✓ | Naïve + Experienced | Proof-of-concept study; no resistance-emergence | ||||
Vertex | Telaprevir (1125 mg BID) | VX-222 (100 mg or 400 mg BID) | 12 weeks | ✓ | ✓ | No | No published results | |||
Bristol- Myers Squibb | BMs-650032 (600 mg BID) | BMs-790052 (60 mg QD) | 24 weeks | ✓ | ✓ | Prior null- responders Only | Frequent virologic breakthrough in Gt1a patients in Daa-only- study arm during first 12 weeks | |||
Boehringer Ingelheim | BI 201335 (120 mg QD) | BI 207127 (400 mg or 600 mg TID) | 4 weeks | ✓ | No | 100% RvR in patients treated with the higher dose of BI 207127/RBv | ||||
Gilead | Gs-9256 (75 mg BID) | Tegobuvir (40 mg BID) | 4 weeks | ✓ | ✓ | ✓ | No | RBV delayed/reduced virologic breakthrough | ||
Abbott | ABT-450/r | ABT-072 | 12 weeks | ✓ | No | No published results | ||||
Pharmasset | PsI-7977 + PsI-938 | 1-2 weeks | ✓ | No | No published results | |||||
Idenix** | IDX320 | IDX184 |